McKesson Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

Is McKesson Corporation (MCK) A Good Stock To Buy Now?

AI-generated analysis

πŸ“‰ MCK shares traded at $763.91 on June 23, 2026, down from nearly $1,000 following a fiscal 2026 Q4 revenue miss.

πŸ›οΈ McKesson operates in a U.S. pharmaceutical distribution oligopoly with Cencora and Cardinal Health, controlling most of the market.

πŸ’° The company generated $5.4 billion in free cash flow during fiscal 2026 despite low operating margins of roughly 1.5%.

πŸ“‰ Management has reduced share count by more than 60% over two decades while tying compensation to return on invested capital.

πŸš€ The Oncology and Multi-Specialty segment achieved 31% revenue growth and 53% operating profit growth in fiscal 2026.

πŸ“ˆ Return on invested capital reached approximately 70%, highlighting efficient capital deployment across the business.

πŸ’Έ A newly authorized $5 billion share repurchase program signals a commitment to returning value to shareholders.

🎯 Conservative intrinsic value estimates range from $885 to $1,275 per share, implying 18% to 70% upside.

Bullish Signals
  • McKesson is described as a dominant player in pharmaceutical distribution with significant competitive advantages through scale and deep customer relationships.
  • The company generated $5.4 billion in free cash flow for fiscal 2026, demonstrating strong cash generation capabilities despite low operating margins.
  • Management has aggressively repurchased stock over the past two decades, reducing share count by more than 60% to enhance per-share growth.
  • The high-margin Oncology and Multi-Specialty segment delivered 31% revenue growth and 53% operating profit growth in fiscal 2026.
  • McKesson benefits from favorable long-term tailwinds including an aging U.S. population and growing demand for GLP-1 therapies.
  • The company achieved a return on invested capital of approximately 70%, indicating highly efficient use of capital.
  • A newly authorized $5 billion share repurchase program provides additional support to shareholder value.
Risk Factors
  • McKesson recently missed its fiscal 2026 fourth-quarter revenue target, contributing to a significant decline in share price from nearly $1,000.
  • The company operates with low operating margins of roughly 1.5%, which limits profitability compared to higher-margin healthcare segments.
Full Analysis
McKesson Corporation (MCK) is presented as a compelling long-term compounder with a share price of $763.91 as of June 23, 2026. Despite a recent decline from nearly $1,000 driven by a fiscal 2026 fourth-quarter revenue miss, the article argues the core investment thesis remains intact due to its dominant position in pharmaceutical distribution and disciplined capital allocation. Operating within a rational oligopoly alongside Cencora and Cardinal Health, McKesson leverages scale and supply chain reliability. The company generates substantial cash flow through an asset-light model, producing $5.4 billion in free cash flow for fiscal 2026 while reducing its share count by over 60% over the past two decades to enhance per-share growth. Strategically shifting toward higher-margin businesses, McKesson's Oncology and Multi-Specialty segment delivered 31% revenue growth and 53% operating profit growth in fiscal 2026. With a return on invested capital of approximately 70% and a newly authorized $5 billion share repurchase program, conservative valuations suggest intrinsic value between $885 and $1,275 per share.